Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Neoadjuvant terapi for tidlig trippel-negativ brystkræft: En responsstyret tilgang med Iparomlimab og Tuvonralimab-injektion i kombination med kemoterapi

Neoadjuvant terapi for tidlig triple-negativ brystkræft: En responsstyret tilgang med Iparomlimab og Tuvonralimab-injektion i kombination med kemoterapi

Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4). This is a prospective clinical study that plans to enroll screened, eligible early-stage breast-cancer patients to receive neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC). After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive four additional AC cycles before surgery. A key feature is the incorporation of an response-guided neoadjuvant therapy(RGN)model to identify sensitive patients who can forgo anthracyclines, thereby reducing long-term cardiotoxicity.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

40

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  • Voluntarily join this study, sign the informed consent form, and demonstrate good compliance;
  • Age: 18-75 years old (at the time of signing the informed consent form);
  • ECOG PS score: 0-1; expected survival time exceeding 6 months;
  • Patients with primary breast cancer confirmed by histopathological or cytological examination;
  • Primary tumor diameter > 2 cm as measured by local standard assessment methods;
  • Judged by the investigator to meet the American Joint Committee on Cancer (AJCC) 8th edition breast cancer TNM staging criteria as cT2-cT4, cN0-cN3, cM0, with locally advanced or early-stage, unilateral, and histologically confirmed invasive breast cancer;
  • According to the latest ASCO/CAP guideline definitions, histopathologically confirmed early-stage triple-negative invasive breast carcinoma meeting all of the following criteria:Tumors are triple-negative on pathological subtyping, defined as: ER-negative: IHC ≤10%; PR-negative: IHC ≤10%; HER2-negative: IHC 0/1+, or IHC 2+ with negative ISH.
  • At least one measurable lesion according to RECIST 1.1;
  • The patient agrees to undergo breast cancer resection surgery when meeting the surgical criteria after neoadjuvant therapy;
  • PD-L1 expression status is known;
  • Major organ functions are in good condition;
  • Female subjects of childbearing potential must have a negative serum pregnancy test within 3 days prior to the first dose. If a female subject of childbearing potential engages in sexual activity with a non-sterilized male partner, the subject must use acceptable and effective contraception from screening onward and agree to continue these precautions until 12 months after the last dose of the study drug; periodic abstinence and rhythm methods are not acceptable contraceptive methods.
  • The subject is willing to provide core needle biopsy tissue samples for research analysis.

Exclusion Criteria:

  • Patients with stage IV metastatic breast cancer or other patients deemed by the investigator as unable to achieve curative surgical resection through neoadjuvant therapy;
  • Patients with inflammatory breast cancer;
  • Patients who have had or currently have other malignancies within the past 3 years. The following two conditions may be eligible: other malignancies treated with a single surgical procedure, achieving continuous 5-year disease-free survival (DFS); cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)];
  • Breast cancer patients who have received antitumor therapies such as chemotherapy, endocrine therapy, or immune checkpoint inhibitors within the past 3 years, or who have undergone breast surgery (except diagnostic biopsy for primary breast cancer);
  • Patients who have undergone major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of study treatment (except diagnostic biopsy for primary breast cancer);
  • Presence of any active autoimmune disease or a history of autoimmune disease;
  • Patients currently using immunosuppressants or systemic hormonal therapy for immunosuppressive purposes (at a dose >10 mg/day prednisone or equivalent steroids) and continuing such treatment within 2 weeks prior to enrollment;
  • Allergy to any study drug or any component or excipient of the drug;
  • Patients with concomitant diseases judged by the investigator as seriously endangering the subject's safety or affecting study completion, or those deemed unsuitable for enrollment for other reasons.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: QL1706 Combination Therapy

neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC).

Participants receive QL1706 every 3 weeks (Q3W) + Albumin-bound paclitaxel every 3 weeks (Q3W) + Cisplatin (Q3W) x 4 cycles. After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive QL1706 Q3W + epirubicin Q3W + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy before surgery.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
tpCR (ypT0/is ypN0)
Tidsramme: Op til cirka 27-30 uger
Op til cirka 27-30 uger

Sekundære resultatmål

Resultatmål
Tidsramme
Radiologisk komplet responsrate (iCR)
Tidsramme: Op til cirka 27-30 uger
Op til cirka 27-30 uger
udnyttelsesrate for epirubicin-cyclophosphamide-regimet
Tidsramme: Op til cirka 16 uger
Op til cirka 16 uger
Hændelsesfri overlevelse (EFS) vurderet af undersøger
Tidsramme: Op til cirka 8 år
Op til cirka 8 år
Procentdel af deltagere, der oplever en bivirkning (AE)
Tidsramme: Op til cirka 60 uger
Op til cirka 60 uger
Overlevelse i alt (OS)
Tidsramme: Op til cirka 8 år
Op til cirka 8 år
Score for sundhedsrelateret livskvalitet (HR-QoL)
Tidsramme: Op til cirka 27-30 uger
Op til cirka 27-30 uger

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studiestol: Yongsheng Jia, Tianjin Medical University Cancer Institute and Hospital
  • Ledende efterforsker: Jun Zhang, Tianjin Medical University Cancer Institute and Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

14. april 2026

Primær færdiggørelse (Anslået)

30. december 2028

Studieafslutning (Anslået)

30. december 2029

Datoer for studieregistrering

Først indsendt

19. januar 2026

Først indsendt, der opfyldte QC-kriterier

19. januar 2026

Først opslået (Faktiske)

28. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. september 2026

Sidst verificeret

1. januar 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • E20251311

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner